Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors - PubMed (original) (raw)
. 2010 Jul;17(7):892-904.
doi: 10.1038/gt.2010.17. Epub 2010 Mar 18.
P Nokisalmi, S Escutenaire, M Särkioja, M Raki, V Cerullo, L Kangasniemi, L Laasonen, C Ribacka, K Guse, E Haavisto, M Oksanen, M Rajecki, A Helminen, A Ristimäki, A Karioja-Kallio, E Karli, T Kantola, G Bauerschmitz, A Kanerva, T Joensuu, A Hemminki
Affiliations
- PMID: 20237509
- DOI: 10.1038/gt.2010.17
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors
S Pesonen et al. Gene Ther. 2010 Jul.
Abstract
Eighteen patients with refractory and progressive solid tumors were treated with a single round of triple modified oncolytic adenovirus (Ad5/3-Cox2L-D24). Ad5/3-Cox2L-D24 is the first non-Coxsackie-adenovirus receptor-binding oncolytic adenovirus used in humans. Grades 1-2 flu-like symptoms, fever, and fatigue were seen in most patients, whereas transaminitis or thrombocytopenia were seen in some. Non-hematological grades 3-5 side effects were seen in one patient with grade 3 ileus. Treatment resulted in high neutralizing antibody titers within 3 weeks. Virus appeared in serum 2-4 days after treatment in 83% of patients and persisted for up to 5 weeks. One out of five radiologically evaluable patients had partial response (PR), one had minor response (MR), and three had progressive disease (PD). Two patients scored as PD had a decrease in tumor density. Tumor reductions not measurable with Response Evaluation Criteria In Solid Tumors (RECIST) were seen in a further four patients. PR, MR, stable disease, and PD were seen in 12, 23.5, 35, and 29.5% of tumor markers analyzed, respectively (N=17). Ad5/3-Cox2L-D24 appears safe for treatment of cancer in humans and extended virus circulation results from a single treatment. Objective evidence of anti-tumor activity was seen in 11/18 (61%) of patients. Clinical trials are needed to extend these findings.
Similar articles
- Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.
Nokisalmi P, Pesonen S, Escutenaire S, Särkioja M, Raki M, Cerullo V, Laasonen L, Alemany R, Rojas J, Cascallo M, Guse K, Rajecki M, Kangasniemi L, Haavisto E, Karioja-Kallio A, Hannuksela P, Oksanen M, Kanerva A, Joensuu T, Ahtiainen L, Hemminki A. Nokisalmi P, et al. Clin Cancer Res. 2010 Jun 1;16(11):3035-43. doi: 10.1158/1078-0432.CCR-09-3167. Epub 2010 May 25. Clin Cancer Res. 2010. PMID: 20501623 Clinical Trial. - Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, Partanen K, Karli E, Haavisto E, Oksanen M, Karioja-Kallio A, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A, Hemminki A. Pesonen S, et al. Int J Cancer. 2012 Apr 15;130(8):1937-47. doi: 10.1002/ijc.26216. Epub 2011 Aug 8. Int J Cancer. 2012. PMID: 21630267 Clinical Trial. - A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL, Liu HL, Zhang XR, Xu JP, Hu WK, Liang M, Chen SY, Hu F, Chu DT. Li JL, et al. Gene Ther. 2009 Mar;16(3):376-82. doi: 10.1038/gt.2008.179. Epub 2008 Dec 25. Gene Ther. 2009. PMID: 19092859 Clinical Trial. - JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Merrick AE, Ilett EJ, Melcher AA. Merrick AE, et al. Curr Opin Investig Drugs. 2009 Dec;10(12):1372-82. Curr Opin Investig Drugs. 2009. PMID: 19943208 Review. - Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S, Gao L, Yeagy B, Reid T. Kumar S, et al. Curr Opin Mol Ther. 2008 Aug;10(4):371-9. Curr Opin Mol Ther. 2008. PMID: 18683102 Review.
Cited by
- Role of Fiber Shaft Length in Tumor Targeting with Ad5/3 Vectors.
Richter M, Wang H, Lieber A. Richter M, et al. Genes (Basel). 2022 Nov 7;13(11):2056. doi: 10.3390/genes13112056. Genes (Basel). 2022. PMID: 36360292 Free PMC article. - Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19.
Cimolai N. Cimolai N. SN Compr Clin Med. 2021;3(10):2093-2108. doi: 10.1007/s42399-021-00992-3. Epub 2021 Jun 22. SN Compr Clin Med. 2021. PMID: 34179695 Free PMC article. Review. - Viral vector platforms within the gene therapy landscape.
Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Bulcha JT, et al. Signal Transduct Target Ther. 2021 Feb 8;6(1):53. doi: 10.1038/s41392-021-00487-6. Signal Transduct Target Ther. 2021. PMID: 33558455 Free PMC article. Review. - Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy.
Deng S, Iscaro A, Zambito G, Mijiti Y, Minicucci M, Essand M, Lowik C, Muthana M, Censi R, Mezzanotte L, Di Martino P. Deng S, et al. Nanomaterials (Basel). 2021 Jan 8;11(1):144. doi: 10.3390/nano11010144. Nanomaterials (Basel). 2021. PMID: 33435600 Free PMC article. - Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.
Taipale K, Tähtinen S, Havunen R, Koski A, Liikanen I, Pakarinen P, Koivisto-Korander R, Kankainen M, Joensuu T, Kanerva A, Hemminki A. Taipale K, et al. Oncotarget. 2018 Jan 5;9(5):6320-6335. doi: 10.18632/oncotarget.23967. eCollection 2018 Jan 19. Oncotarget. 2018. PMID: 29464075 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials